Ad-din Pharmaceuticals Ltd®

What Ad-din Pharmaceuticals Ltd® does

Ad-din Pharmaceuticals Limited is a privately held Bangladeshi pharmaceutical manufacturer founded on 1 August 1996, headquartered at 2, Bara Maghbazar, Dhaka-1217, with a manufacturing facility at BSCIC Industrial Estate, Jhumjhumpur, Jashore. The company produces branded generic medicines across multiple dosage forms — solid tablets, capsules, syrups, powder for suspensions, oral solutions, creams, and ointments — spanning more than 113 SKUs across 21+ therapeutic categories including antibiotics, anti-ulcerants, cardiovascular drugs, NSAIDs, anti-diabetics, antipsychotics, antivirals, vitamins and minerals, analgesics, gastrointestinal, and respiratory treatments. Recent launches (2024–2025) have extended the portfolio into ophthalmology (eye drops) and topical dermatology, with pediatric products pre-announced for 2026. The company employs between 62 and 98+ people according to differing sources and operates under the regulatory oversight of the Directorate General of Drug Administration (DGDA), the Directorate General of Health Services (DGHS), and the Ministry of Health and Family Welfare, Bangladesh.

The company's go-to-market is sales-led and entirely domestic. A direct sales team promotes specialties across Bangladesh with a territory design that covers both rural and urban areas, supported by a distribution channel the company describes as reaching the distant corners of the country. There are no disclosed exports, no institutional customer logos, and no enterprise contracts; the customer base consists of Bangladesh healthcare consumers and providers purchasing through standard retail and clinical channels. Pricing is positioned at the affordable end of the market but is not publicly disclosed. Revenue, funding, and ownership structure are not disclosed in available data; the company is privately held with no known external institutional investors or parent entity.

The business model is a conventional branded-generics manufacturer reliant on DGDA-licensed production and a national direct-sales distribution network. There are no AI/ML capabilities, no API or software products, no patents or trademarks disclosed, and no awards or certifications beyond DGDA regulatory compliance. Digital presence is limited to organic social channels (Facebook, LinkedIn, YouTube) and a corporate website. The principal operational signals of strategic direction are the cadence of new product launches and the planned entry into pediatric formulations, both of which represent incremental line extensions within the existing domestic market rather than expansion into new geographies or business models.

Name

Ad-din Pharmaceuticals Ltd®

Legal name

Ad-din Pharmaceuticals Limited

Website

https://addinpharma.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

51–100 employees

Short description

Ad-din Pharmaceuticals Limited is a privately held Bangladeshi manufacturer of branded generic medicines, producing 113+ products across antibiotics, cardiovascular, anti-diabetics, ophthalmology, and other therapeutic categories for the domestic Bangladesh healthcare market through a direct sales and distribution network.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

OTC & Consumer Health Distributors (HLAIAJAC), Ophthalmology Pharmaceuticals (HLAIAAAL), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Branded generics
• Dosage formulations
• Therapeutic medicines

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and selling branded generic pharmaceutical products covering therapeutic categories such as antibiotics, anti-ulcerants, cardiovascular, NSAIDs, anti-diabetics, antipsychotic, antiviral, vitamins and minerals

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Ad-din Pharmaceuticals Ltd manufactures and markets branded generic pharmaceutical products in Bangladesh, producing more than 113 products across multiple dosage forms (tablets, capsules, syrups, powders for suspensions, oral solutions, creams, and ointments). The portfolio spans therapeutic categories including antibiotics, anti-ulcerants, cardiovascular drugs, NSAIDs, anti-diabetics, antipsychotics, antivirals, vitamins and minerals, analgesics, antihistamines, gastrointestinal, and respiratory medications, distributed nationally through a direct sales team.

Product overview

Ad-din Pharmaceuticals Ltd is a Bangladeshi pharmaceutical company that manufactures and markets branded generic medicines. The company produces more than 113 products in various dosage forms including solid tablets, capsules, syrups, powder for suspensions, oral solutions, creams, and ointments. Their portfolio covers therapeutic categories such as antibiotics, anti-ulcerants, cardiovascular drugs, NSAIDs, anti-diabetics, antipsychotics, antivirals, vitamins and minerals, analgesics, antihistamines, and respiratory medications. The product lineup includes DRT 30/60 Capsule for cardiovascular conditions, I-Clo Eye Drop, Moxflo Eye Drop, Olosol Eye Drop, and Vofox Eye Drop for ophthalmic treatments, Mita Syrup, Povibac ointments, Somazole MUPS tablets for gastrointestinal conditions, and Topkill ointment. The company has also introduced eye drop products (Moxflo, I-Clo, Olosol, Vofox) and upcoming products including Bilto Kids and Bilto Oral Solution.

Differentiator

Problem solved

Functional benefit

Products and services

• DRT 30 Capsule A branded generic capsule product for treating cardiovascular conditions in Bangladesh patients.
• DRT 60 Capsule A branded generic capsule product for treating cardiovascular conditions in Bangladesh patients.
• I-Clo Eye Drop An eye drop medication for ophthalmic conditions.
• Mita Syrup 100 ml A branded generic syrup formulation in 100ml packaging.
• Moxflo Eye Drop An antibiotic eye drop medication for treating eye infections.
• Olosol DS Eye Drop A dual-strength eye drop formulation for ophthalmic treatment.
• Olosol Eye Drop An eye drop medication for treating ophthalmic conditions.
• Povibac 10g Ointment A topical ointment formulation in 10g packaging.
• Povibac 25g Ointment A topical ointment formulation in 25g packaging.
• Somazole MUPS 20 Tablet A branded generic tablet formulation for gastrointestinal conditions.
• Somazole MUPS 40 Tablet A branded generic tablet formulation for gastrointestinal conditions.
• Topkill 10 Ointment A topical ointment formulation.
• Vofox Eye Drop An eye drop medication for treating ophthalmic conditions.

Quantifiable outcome

• More than 113 products in various dosage forms covering broader therapeutic categories

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core and minor.

• Directorate General of Drug Administration (DGDA)coreOthersRegulatory oversight and compliance partner for pharmaceutical manufacturing and distribution in Bangladesh. Company operates under DGDA regulatory framework.
• Directorate General of Health Services (DGHS)minorOthersGovernment health services body in Bangladesh; company operates within the national healthcare framework.
• Ministry of Health and Family Welfare BangladeshminorOthersParent ministry overseeing healthcare policy and pharmaceutical regulations in Bangladesh.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ACI Limited (Pharma Division): Diversified Bangladeshi conglomerate with a pharmaceutical division manufacturing branded generics in antibiotics, cardiovascular, and respiratory segments. Direct comparable on domestic Bangladesh focus and branded-generic model, with broader conglomerate backing and consumer health adjacencies.
• General Pharmaceuticals Limited: Bangladesh-based branded generics manufacturer with portfolio overlap in antibiotics, cardiovascular, and anti-ulcerants. Comparable on the domestic Bangladesh focus, branded-generic model, and similar mid-tier scale profile.
• Healthcare Pharmaceuticals: Bangladesh-based pharmaceutical company producing branded generics across similar therapeutic categories as Ad-din (cardiovascular, anti-ulcerants, antibiotics, antidiabetics). Highly comparable on company scale, single-market focus, and therapeutic breadth, making it a strong mid-tier peer benchmark.
• Drug International Limited: Bangladesh-based pharmaceutical manufacturer producing branded generics across multiple therapeutic categories for the domestic market. Closely comparable to Ad-din on size, geographic focus (Bangladesh-only), and therapeutic breadth, including overlap in ophthalmology and anti-ulcerant segments.
• Incepta Pharmaceuticals: Bangladesh's second-largest pharmaceutical company by domestic sales, producing branded generics across a broad therapeutic range including sterile injectables, biosimilars, and ophthalmics. Highly comparable on branded-generic positioning and therapeutic breadth, with material advantages in scale and modern manufacturing capacity.
• Beximco Pharmaceuticals: One of Bangladesh's leading exporters of branded generic pharmaceuticals with a portfolio covering antibiotics, cardiovascular, anti-diabetics, and respiratory. Direct comparable on product mix and target market; differentiated by larger scale, US FDA-approved facilities, and significant export revenue.
• Square Pharmaceuticals: Bangladesh's largest pharmaceutical manufacturer by revenue, producing branded generics across virtually all therapeutic categories including cardiovascular, antibiotics, and ophthalmics. Most direct comparable to Ad-din in terms of business model (branded generics for Bangladesh), with the key contrast being Square's far larger scale, multi-site manufacturing, and export footprint.
• Renata Limited: Bangladesh-based pharmaceutical manufacturer with a strong animal health and branded generics portfolio, including antibiotics, cardiovascular, and endocrinology products. Comparable on the domestic branded-generic business model, though Renata is more diversified across animal health and consumer products.
• Aristopharma Limited: Bangladesh pharmaceutical manufacturer producing branded generics across antibiotics, cardiovascular, NSAIDs, and antidiabetics, with growing ophthalmic and dermatology lines. Comparable on product mix and target customer base, with somewhat larger manufacturing scale and emerging sterile injectables capability.
• Eskayef Pharmaceuticals: Bangladesh-based branded generics manufacturer owned by Transcom Group, producing across antibiotics, cardiovascular, antidiabetics, and respiratory. Closely comparable in therapeutic mix and target market, distinguished by multinational-grade manufacturing facilities and growing export presence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@ad-dinpharmaceuticalsltd.3329
• Facebookfacebook.com/addinpharma
• LinkedInlinkedin.com/company/ad-din-pharmaceuticals-ltd

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ad-din Pharmaceuticals Ltd®